Meningococcal Vaccines Market

The global Market is valued at USD 3.61 Billion in 2023 and is projected to reach a value of USD 6.35 Billion by 2032 at a CAGR (Compound Annual Growth Rate) of 6.5% between 2024 and 2032.

Key Highlights

• The North American region predominantly led the market in 2023, with 58.3% of the total market share,
• The Asia Pacific region is projected to observe the fastest growth during the forecast period,
• In 2023, the Conjugate Vaccines segment took the lead in the market, contributing a 52.3% substantial revenue share,
• The Serotype B segment significantly contributed to the market’s expansion, constituting over 36.5% of the overall revenue share in 2023,
• Government-backed vaccination programs and public health campaigns to prevent meningococcal infections contribute to global market growth.

Regional Overview

The North American market accounted for 58.3% of the global market revenues in 2023. This is because of factors like increased awareness about meningococcus diseases, a robust healthcare system, and active immunization programs. Key players in this market include Pfizer, GlaxoSmithKline, and Sanofi, offering various vaccines targeting different serotypes of meningococcal disease. Government support further strengthens market demand through vaccination programs and health promotion campaigns. While continued R&D activity drives innovation, the region's well-established healthcare systems facilitate the widespread adoption of vaccines.

U.S. Market Overview

The market in the United States, with a valuation of USD 1.56 Billion in 2023, is projected to reach around USD 2.27 Billion by 2032. A significant Compound Annual Growth Rate (CAGR) of 4.3% from 2024 to 2032 is projected in this forecast. The U.S. market is thriving due to the robust healthcare infrastructure and proactive immunization efforts. Government-backed vaccination programs and public health campaigns further drive market growth.

Type Overview

In 2023, substantial expansion was observed in the overall market within the Conjugate Vaccines category, commanding a revenue share of 52.3%. The Type segment is divided into Polysaccharide Vaccines, Conjugate Vaccines, and Combination Vaccines a. This segment is important in developing vaccine technology, using conjugated techniques to enhance immune response. Conjugate Vaccines result in a more robust and prolonged immune response, especially crucial for the fight against Meningococcus infection, when bacterial polysaccharides are linked to carrier proteins. Additionally, government initiatives promoting vaccination programs & investments in healthcare infrastructure contribute to market expansion. With ongoing research & development efforts, the Conjugate Vaccines segment is poised for continued growth, offering improved protection against meningococcal pathogens worldwide.

Serotype Overview

In 2023, there was significant growth in the Serotype B segment, over 36.5% of the market share. Based on the Serotype, the Meningococcal Vaccines market is segmented into Serotype A, Serotype B, Serotype C, Serotype W-135, and Serotype Y. The dominance of Serotype B in the global market can be credited to the availability of potent vaccines like Trumenba & Bexsero, alongside the escalating disease burden posed by MenB worldwide. In North America and Europe, Serotype B is the primary culprit behind meningococcal disease, contributing to approximately half of all reported cases in these regions. Furthermore, ongoing research endeavors to develop pentavalent vaccines, encompassing protection against Serotype B, are poised to amplify market growth throughout the forecast period. Conversely, the Serotype C segment will witness the swiftest expansion over the forecast period. This surge can be attributed to vaccines' remarkable efficacy and increasing integration into national vaccination programs. Notably, countries such as the U.K., Australia, Belgium, France, Germany, Iceland, Ireland, and the Netherlands, among others, have adopted the serogroup C conjugate vaccine into their National Immunization Program, further bolstering the segment's growth trajectory.

Key Trends

1. Continued advances in vaccine technology, such as developing conjugate vaccines, are driving innovation in the global meningitis vaccination market.
2. Vaccine manufacturers worldwide are increasing the indications for meningococcus vaccines to target different age groups and provide protection against a variety of serotypes.
3. Consolidation is taking place in the market through mergers, acquisitions, and strategic cooperation between key players, with a view to strengthening their product portfolios and increasing their presence on the market.
4. Ongoing research & development efforts are focused on developing next-generation vaccines with improved efficacy, safety profiles, and broader coverage against meningococcal strains.

Premium Insights

The Global Meningococcal Vaccines Market operates within a complex landscape influenced by the prevalence and virulence of various serogroups of Neisseria meningitidis worldwide. While serogroups A, B, and C traditionally dominate, the emergence of group Y, particularly in the United States, adds to the dynamic. In the African meningitis belt, group A epidemics occur cyclically, leading to significant morbidity and mortality, especially among children and young adults. Recent outbreaks of group W135 in the African belt and Saudi Arabia and group C strains in Western countries underscore the ongoing threat. Despite available medical services, the disease maintains high case-fatality rates (5%-15%), necessitating effective preventive measures. Existing vaccines, primarily based on group-specific capsular polysaccharides or conjugates, offer varying degrees of immunogenicity and safety. While polysaccharide vaccines are highly immunogenic but ineffective in young children, introducing serogroup C conjugate vaccines presents a promising solution even for the youngest demographic. However, challenges persist, including the lack of readily available monovalent polysaccharide vaccines and the modest efficacy of vaccines targeting group B meningococci in both children and adults.

‹›

Report Coverage & Deliverables

PDF report & online dashboard will help you understand:

• Real-Time Data Updates:
• Competitor Benchmarking
• Market Trends Heatmap
• Custom Research Queries
• Market Sentiment Analysis
• Demographic and Geographic Insights

Book Demo

Get Access Now

Track market trends LIVE & outsmart rivals with our Premium Data Intel Tool: Vantage Point

Market Dynamics

The Global Meningococcal Vaccines Market experiences a significant development as GSK's 5-in-1 meningococcal ABCWY vaccine candidate has recently entered regulatory review by the US FDA. If approved, this vaccine promises broad coverage against the five most common groups of bacteria causing invasive meningococcal disease, potentially simplifying immunization schedules by reducing the number of required injections. Accepting the Biologics License Application (BLA) marks a pivotal step, with a Prescription Drug User Fee Act (PDUFA) action date set for February 14, 2025. Leveraging the antigenic components of GSK's established Meningococcal Vaccines, Bexsero and Menveo, the MenABCWY combination targets the Neisseria meningitidis serogroups A, B, C, W, and Y, prevalent globally. To reduce the risk of meningococcal disease in unvaccinated adolescents and possibly prevent outbreaks, simplifying vaccination procedures could contribute to increasing completion rates and coverage. Considering the severe consequences of IMD, including high fatality rates and long-term complications, particularly among late teens & young adults, the introduction of this vaccine candidate holds promise for mitigating the disease's impact worldwide.

The Global Meningococcal Vaccines Market witnesses a significant milestone with the FDA's approval of PENBRAYA™, marking the first pentavalent vaccine targeting the five most prevalent serogroups responsible for meningococcal disease in adolescents and young adults aged 10 through 25 years. PENBRAYA offers unparalleled serogroup coverage, including meningococcal groups A, B, C, W, and Y, streamlining vaccination schedules and potentially enhancing compliance in the U.S. market. The results of the ongoing Phase 2 and 3 clinical studies, which show that PENBRAYA® is not immunogenic compared to current vaccines such as Trumenba® + Menveo®, are supported by a favorable safety profile. This approval underlines Pfizer's commitment to developing innovative vaccines, leveraging over two decades of experience against meningococcal disease and strengthening its diversified vaccine portfolio.

The global Meningococcal Vaccines market can be categorized as Type, Serotype, and Region.

Competitive Landscape

The Global Meningococcal Vaccines market is dynamic and multifaceted, characterized by intense rivalry among key players striving for market dominance. Top pharmaceutical companies such as GlaxoSmithKline, Pfizer, and Sanofi are prominent contenders, leveraging their extensive R&D capabilities and global reach to develop innovative vaccines and expand market share. Strategic collaborations, mergers, & acquisitions are common tactics employed to strengthen product portfolios and gain a competitive edge. Furthermore, stringent regulatory requirements and the need for substantial investment in manufacturing facilities present barriers to entry, consolidating the market's competitive dynamics. With the growing demand for Meningococcal Vaccines driven by rising disease prevalence and increasing immunization efforts, competition is expected to intensify, fostering innovation and driving market expansion.

Recent Market Developments

Walvax Biotechnology's Phase 4 Clinical Investigation

• In November 2023, Walvax Biotechnology Co. Ltd. (“Walvax”, 300142. SZ) announced that representatives from Walvax have disclosed the safety and non-inferior immunogenicity findings of its quadrivalent meningococcal polysaccharide vaccine (MPV ACYW135), compared to the quadrivalent meningococcal conjugate vaccine (Menactra®), in phase 4 clinical investigation carried out at the Centre pour le Développement des Vaccins du Mali (CVD-Mali) in Bamako, Mali, spanning from December 2020 to July 2023. These findings were presented at two prominent scientific conferences held during the fourth quarter of 2023.

MenFive® Prequalification by WHO

• In July 2023, MenFive®, the inaugural conjugate vaccine shielding against the five primary triggers of meningococcal meningitis in Africa, has earned prequalification from the World Health Organization (WHO). Developed through a 13-year partnership between Serum Institute of India Pvt. Ltd. (SIIPL) and PATH, with vital support from the UK government's Foreign, Commonwealth, and Development Office, MenFive® offers defense against meningococcal serogroups A, C, W, Y, and X. Its formulation aims to eradicate yearly meningitis outbreaks and epidemics within the African meningitis belt, spanning 26 nations from Senegal and The Gambia in the west to Ethiopia in the east. Additionally, it stands as the sole vaccine preventing meningitis stemming from meningococcal group X, a pathogen increasingly associated with meningitis outbreaks across Africa.

​

The global Meningococcal Vaccines market can be categorized as Type, Age Group, Serotype, Distribution Channel, and Region.